CytomX pens Probody deal with Bristol
CytomX Therapeutics Inc. (next-generation, targeted antibodies) licensed Bristol-Myers Squibb Co. exclusive worldwide rights to discover, develop, and sell Probodies interacting with up to four immuno-oncology targets, including cytotoxic T-lymphocyte antigen-4 (CTLA-4).
- Drug Discovery Tools
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com